Phytotherapy in the treatment of benign prostatic hyperplasia: An update

Urology

Volumn 53, Issue 4, 1999, Pages 671-678

  Lowe, Franklin C ^a,b   Fagelman, Elliot ^a,b  

^a College of Physicians and Surgeons ^*  (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CERNITIN; FATTY ACID; FINASTERIDE; FLAVONOID; FLUTAMIDE; LECTIN; PHYTOESTROGEN; PHYTOSTEROL; PLANT EXTRACT; POLYSACCHARIDE; PYGEUM AFRICANUM EXTRACT; SITOSTEROL; TERPENOID; URTICA DIOICA EXTRACT; VEGETABLE OIL;

BLADDER FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; HUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; REVIEW; SABAL; SEXUAL FUNCTION; TREATMENT OUTCOME; URODYNAMICS;

ANDROGEN ANTAGONISTS; CLINICAL TRIALS; HUMANS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; SECALE CEREALE; SERENOA; URODYNAMICS;

EID: 0033119883     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00664-5     Document Type: Review

References (55)

1. Lowe FC, and Ku JC: Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 48: 12-20, 1996.
2. Marwick C: Growing use of medicinal botanicals forces assessment by drug regulators. JAMA 273: 607-609, 1995.
3. Dreikorn K, Borkowski A, Braeckman J, et al: Other medical therapies, in Denis L, Griffiths K, and Murphy G (Eds): Proceedings of the Fourth International Consultation on Benign Prostatic Hyperplasia (BPH), July 1997. Plymouth, UK, Health Publications, 1998, pp 635-659.
4. Lowe F: What I tell patients about phytotherapeutic agents for benign prostatic hyperplasia. AUA News 3: 12, 1998.
5. Astin JA: Why patients use alternative medicine: result of a national study. JAMA 279: 1548-1553, 1998.
6. Lowe FC, and Fagelman E: Phytotherapy in the treatment of benign prostatic hyperplasia. Curr Opin Urol 8: 27-29, 1998.
7. Lowe FC: Saw palmetto berry in the treatment of benign prostatic hyperplasia. Clin Res Reg Affairs 14: 53-66, 1997.
8. Plosker G, and Grogden RM: Serenoa repens (Permixon®) - a review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9: 379-395, 1996.
9. Ravenna L, Di Silverio F, Russo M, et al: Effects of the lipidosterolic extract of Serenoa repens (Permixon®) on human prostatic cell lines. Prostate 29: 219-230, 1996.
10. Di Silverio F, D'Eramo G, Lubrano C, et al: Evidence that Serenoa repens extract displays an antiestrogenic activity in prostatic tissue of benign prostatic hypertrophy patients. Eur Urol 21: 309-314, 1992.
11. Iehle C, Delos S, Guirou O, et al: Human prostatic steroid 5-reductase isoforms: a comparative study of selective inhibitors. J Steroid Biochem Mol Biol 54: 273-279, 1995.
12. Bayne CW, Grant ES, Chapman K, et al: Characterisation of a new coculture model for BPH which expresses 5-al-pha-reductase types I and II: the effects of Permixon on DHT formation (abstract 70). Fourth International Consultation on BPH, Paris, 1997, p 70.
13. Vacher P, Prevarskaya N, Skryma R, et al: The lipidosterolic extract from Serenoa repens interferes with prolactin receptor signal transduction. J Biomed Sci 2: 357-365, 1995.
14. Paubert-Braquet M, Raynaud JP, Braquet P, et al: Permixon {lipid sterolic extract of serenoa repens (LSESr)} and some of its components inhibits b-FGF- and EGF-induced proliferation of human prostate organotypic cell lines (abstract 74). Fourth International Consultation on BPH, Paris, 1997, p 74.
15. Paubert-Braquet M, Servent N, Serikoff A, et al: Permixon (lipido-sterol extract of Serenoa repens-LSESr) inhibits estrogen-androgen-induced prostate enlargement in the rat. Pharmacol Res 31(suppl):31-35, 1995.
16. Paubert-Braquet M, Cousse H, Raynaud JP, et al: Effect of lipidosterolic extract of Serenoa repens (Permixon®) on the inophore A 23187-stimulated-production of leukotriene B4 (LTB4) from human polymorphonuclear neutrophils (abstract 72). Fourth International Consultation on BPH, Paris, 1997.
17. Di Silverio F, Sciarra A, D'Eramo G, et al: Response to tissue androgen and epidermal growth factor concentrations to the administration of finasteride, flutamide and Serenoa repens in patients with BPH (abstract). Eur Urol 30(suppl 2): 80, 1996.
18. Weisser H, Tunn S, Behnke B, et al: Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5-alpha-reductase activity in human benign prostatic hyperplasia. Prostate 28: 300-306, 1996.
19. Helpap B, Oehler U, Weisser H, et al: Morphology of benign prostatic hyperplasia after treatment with Sabal extract IDS 89 or placebo. J Urol Pathol 3: 175-182, 1995.
20. Rhodes L, Primka RL, Berman C, et al: Comparison of finasteride (Proscar®), a 5-alpha-reductase inhibitor and various commercial plant extracts in in vitro and in vivo 5-alpha-reductase inhibition. Prostate 22: 43-51, 1993.
21. Casarosa C, Coscio di Coscio M, and Fratta M: Lack of effects of a liposterolic extract of Serenoa repens on plasma levels of testosterone, follicle-stimulating hormone, and leuteinizing hormone. Clin Ther 5: 585-588, 1988.
22. Strauch G, Perles P, Vergult G, et al: Comparison of finasteride (Proscar®) and Serenoa repens (Permixon®) in the inhibition of 5-alpha reductase in healthy male volunteers. Eur Urol 26: 247-252, 1994.
23. Braeckmann J: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a multicenter open study. Curr Ther Res 55: 776-785, 1994.
24. Gerber GS, Zagaja GP, Bales GT, et al: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 51: 1003-1007, 1998.
25. Descotes JL, Rambeaud JJ, Deschaseaux P, et al: Placebo-controlled evaluation of the efficacy and tolerability of Permixon® in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 9: 291-297, 1995.
26. Lowe FC, Roehrborn CG, Robertson C, et al: Meta-analysis of clinical trials of Permixon® (abstract). J Urol 159(Pt2): 257, 1998.
27. Carraro JC, Raynaud JP, Koch G, et al: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1089 patients. Prostate 29: 231-240, 1996.
28. Denis LJ: Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostatic hyperplasia: a randomized international study of 1098 patients (editorial review). Prostate 29: 241-242, 1996.
29. Lepor H, Williford WO, Barry MJ, et al: The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med 335: 533-539, 1996.
30. Lowe FC: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms (editorial comment). Urology 51: 1007, 1998.
31. Paubert-Braquet M, Momboisse JC, Boichot-Lagente JC, et al: Pygeum arfricanum extract inhibits bFGF and EGF induced proliferation of 3T3 fibrolasts. Biomed Pharmacother 48: 43-47, 1994.
32. Le Brun G, Mellah I, Aubin P, et al: A rationale for the use of Pygeum africanum extract during BPH course is suggested by in vitro proliferation control of human prostate and bladder fibrobasts (abstract). Eur Urol 30(suppl 2): 98, 1996.
33. Yablonsky F, Nicolas V, Riffaud JP, et al: Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts. J Urol 157: 2381-2387, 1997.
34. Paubert-Braquet M, Cave A, Hocquemiller R, et al: Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells. J Lipid Mediat Cell Signal 9: 285-290, 1994.
35. Mathe G, Hallard M, Bourut CH, et al: A Pygeum africanum extract with so-called phyto-estrogenic action markedly reduces the volume of true and large prostatic hypertrophy. Biomed Pharmacother 49: 341-344, 1995.
36. Levin RM, Riffaud JP, Bellamy F, et al: Effects of Tadenan® pretreatment on bladder physiology and biochemistry following partial outlet obstruction. J Urol 156: 2084-2088, 1996.
37. Levin RM, Riffaud JP, Bellamy F, et al: Protective effect of Tadenan® on bladder function secondary to partial outlet obstruction. J Urol 155: 1466-1470, 1996.
38. Andro MC, and Riffaud JP: Pygeum africanum extract for the treatment of patients with benign prostatic hyperplasia: a review of 25 years of published experience. Cur Ther Res 56: 796-817, 1995.
39. Breza J, Dzurny O, Borowka A, et al: Efficacy and acceptability of Tadenan® (Pygeum africanum extract) in the treatment of benign prostatic hyperplasia (BPH): a multi-culture trial in Central Europe. Curr Med Res Opin 14: 127-139, 1998.
40. Abbou CC, Hozneck A, McCarthy C, et al: Alfuzosin,an uroselective alpha-1-blocker versus Pygeum africanum, a plant extract: a randomized controlled trial in patients with symptomatic benign prostatic hypertrophy (BPH) (abstract). Eur Urol 30 (suppl 2): 61, 1996.
41. Valentini F, Besson G, and Nelson P: Modelized analysis of the effect of Tadenan® on human bladder: preliminary study (abstract 48). Fourth International Consultation on BPH, Paris, 1997, p 48.
42. Wagner H, Flachsbarth H, and Vogel G: A new anti-prostatic principle of stinging nettle (Urtica dioica) roots. Phytomedicine 1: 213-224, 1994.
43. --ATPase of the benign prostatic hyperplasia. Planta Med 60: 30-33, 1994.
44. Hryb DJ, Khan MS, Romas NA, et al: The effects of extracts of the roots of the stinging nettle (Urtica dioica) on the interaction of SHBG with its receptor on human prostatic membranes. Planta Med 61: 31-32, 1995.
45. Engelmann U, Boos G, and Kres H: Therapie der benignen Prostathyperplasie mit Bazoton Liquidum. Urologe B 36: 287-291, 1996.
46. Metzker H, and Martin C: Efficacy and safety of the Sabal urtica combination PRO 160/120 in the treatment of patients with benign prostatic hyperplasia (a placebo-controlled double-blind, long-term clinical trial) (abstract 15). Fourth International Consultation on BPH, Paris, 1997, p 15.
47. Metzker M, Kieser M, and Holsher U: Wirksamkeit eines Sabal-Urtica-Kombinationsprapartes bei der Behandlung der benignen Prostatahyperplasie (BPH). Urologe B 36: 292-300, 1996.
48. SokelandJ, and Albrecht J: Kombination aus Sabal- und Uricaextrakt mit Finasterid bei BOH (Stad.Ibis II nach Alken). Urologe A 36: 327-333, 1997.
49. Habib FK, Ross M, Lewenstein A, et al: The identification of a prostate inhibitory substance in a pollen extract. Prostate 26: 133-139, 1995.
50. Dutkiewicz S: Usefulness of Cernilton in the treatment of benign prostatic hyperplasia. Int Urol Nephrol 28: 49-53, 1996.
51. Kassen A, Berges R, and Senge T: Effect of B-sistosterol (Harzol®) on the expression and secretion of growth factors in primary human prostate stromal cell cultures in vitro (abstract 31). Fourth International Consultation on BPH, Paris, 1997, p 31.
52. Berges RR, Windeler J, Trampisch H, et al: Randomized, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Lancet 345: 1529-1532, 1995.
53. Klippel KF, Hilti DM, and Schipp B, for the German BPH-Phytotherapy Study Group: A multicentric, placebo-controlled, double-blind clinical trial of beta-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia. Br J Urol 80: 427-432, 1997.
54. Buck AC: Phytotherapy for the prostate. Br J Urol 78: 325-336, 1996.
55. Lowe FC, Dreikorn K, Borkowski A, et al: A review of the recent placebo-controlled trials utilizing phytotherapeutic agents for the treatment of BPH. Prostate 37: 187-193, 1998.